Eugenia holds a BA in Biological Sciences from Northwestern University Illinois and started her career as a clinical research associate, focusing on cardiovascular and gastrointestinal therapeutic areas. In 2001, she became a market research analyst for Frost & Sullivan and then equity research analyst at Avondale Partners and at Thomas Weisel Partners. In 2006, she joined BioMarin Pharmaceutical, a listed US biotech company in California to create the Investor Relations function. Since 2014, she was Director, Investor Relations for AstraZeneca PLC in London (UK).
